AZA Combined with R-GemOx for Elderly DLBCL Patients
Launched by DAPING HOSPITAL AND THE RESEARCH INSTITUTE OF SURGERY OF THE THIRD MILITARY MEDICAL UNIVERSITY · Jan 12, 2025
Trial Information
Current as of July 09, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a new treatment approach for elderly patients with diffuse large B-cell lymphoma (DLBCL), which is a type of blood cancer. The trial will study the safety and effectiveness of combining two treatments: AZA (azacytidine) and R-GemOx (a mix of rituximab, gemcitabine, and oxaliplatin). This study is specifically for patients aged 60 and older who have been diagnosed with DLBCL and have not received any previous chemotherapy or radiation for their condition.
To be eligible for this trial, participants must understand the study and willingly agree to take part by signing a consent form. They need to have at least one measurable tumor that can be evaluated according to specific guidelines. This trial is not yet recruiting participants, but once it starts, those who join can expect to receive the new treatment and be monitored closely for its effects. It's important to note that certain patients, such as those with other types of lymphoma or specific health issues, may not be able to participate.
Gender
ALL
Eligibility criteria
- Key Inclusion Criteria:
- • 1. Subjects fully understand and voluntarily participate in this study and sign informed consent.
- • 2. Aged ≥60 years, both male and female.
- • 3. Pathologically confirmed DLBCL
- • 4. There must be at least one measurable or evaluable lesion that meets the evaluation criteria for Lugano 2014 lymphoma.
- • 5. No previous chemotherapy or radiotherapy for DLBCL has been received.
- • 6. Expected survival ≥3 months.
- Key Exclusion Criteria:
- • 1. DLBCL combined with other types of lymphoma. Transformed DLBCL.
- • 2. DLBCL with central nervous system invasion.
- • 3. The patients have contraindications to any drug in the combined treatment.
- • 4. Patients with the infection of human immunodeficiency virus (HIV) and/or acquired immunodeficiency syndrome.
- • 5. Mentally ill persons or persons unable to obtain informed consent.
- • 6. The investigators think that the patient is not suitable for the study.
About Daping Hospital And The Research Institute Of Surgery Of The Third Military Medical University
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University is a leading clinical trial sponsor dedicated to advancing medical research and improving patient outcomes. Renowned for its innovative approach to surgical and medical research, the institution combines cutting-edge technology with a team of experienced clinicians and researchers to conduct rigorous clinical trials. With a commitment to ethical standards and patient safety, Daping Hospital aims to translate scientific discoveries into effective therapeutic interventions, contributing significantly to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chongqing, , China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported